Statement Of Cash Flows [Abstract]

Marinomed Biotech AG - Filing #1129987

Concept 2020-01-01 to
2020-12-31
2019-01-01 to
2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income
5,230,000 EUR
3,000 EUR
Adjustments to reconcile profit (loss) other than changes in working capital
2,478,000 EUR
3,564,000 EUR
Adjustments for decrease (increase) in trade and other receivables
2,043 EUR
1,328 EUR
Adjustments for increase (decrease) in trade and other payables
1,337 EUR
8,707,000 EUR
Adjustments for decrease (increase) in other assets
4,000 EUR
3,000 EUR
Adjustments for gain (loss) on disposals, property, plant and equipment
10,000 EUR
0 EUR
Income taxes paid, classified as operating activities
- EUR
44,000 EUR
Finance costs paid, classified as operating activities
2,120,000 EUR
3,822,000 EUR
Finance income received, classified as operating activities
1,000 EUR
2,000 EUR
Cash flows from (used in) investing activities [abstract]
Purchase of interests in associates
- EUR
350,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from exercise of options
3,060,000 EUR
- EUR
Proceeds from issue of ordinary shares
- EUR
22,425 EUR
Proceeds from non-current borrowings
8,000 EUR
4,000 EUR
Repayments of non-current borrowings
2,100,000 EUR
1,891 EUR
Cash repayments of advances and loans from related parties
- EUR
2,263 EUR
Repayments of bonds, notes and debentures
- EUR
248,000 EUR
Payments for share issue costs
117,000 EUR
1,780 EUR
Payments for debt issue costs
- EUR
479,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.